Femasys shares surge 16.05% premarket after Laidlaw initiates Buy rating with $6.50 target, citing FemaSeed’s superior pregnancy rates and expanded market strategy.

Femasys Inc. (NASDAQ:FEMY) surged 16.05% in premarket trading following Laidlaw’s initiation of coverage with a "Buy" rating and a $6.50 price target, implying over 750% upside from its recent $0.76 level. The firm highlighted FemaSeed’s 17.5% pregnancy success rate—superior to traditional IUI methods—and its potential to expand sales by targeting gynecologists, who manage broader patient bases. Additional catalysts included FDA approval to advance its FemBloc birth control device’s U.S. regulatory pathway, regulatory approvals in Europe/UK/New Zealand, and a post-market study aligning with EU standards. Femasys also resolved Nasdaq compliance issues and reported 63.53% year-over-year revenue growth, with analysts forecasting continued expansion. These developments, combined with a strong consensus "Buy" rating from analysts, fueled premarket optimism.